Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
China COVID-19 Vaccines and Antibody Treatments Advancing toward Approvals
Chris Chen, CEO at Shanghai-headquartered WuXi Biologics (HK: 2269), told a reporter that the CRO/CMO is working on 10 neutralizing antibodies from clients for COVID-19 and one vaccine. Because the candidates are making rapid progress, he expects approval for a COVID-19 antibody treatment either “late this year or early next year.” Meanwhile, Sinopharm said three unapproved
All three of the
According to Sinopharm, no serious adverse reaction has been reported from people who received its unapproved vaccine under emergency use rules. While the vaccines are being monitored, Sinopharm and Sinovac have continued overseas Phase III clinical trials with 60,000 people enrolled. Blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, implying that preliminary results from the trials should be available soon.
Disclosure: ChinaBio® has a business relationship with Pfizer.